Loading clinical trials...
Loading clinical trials...
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of rotigotine in subjects with idiopathic PD.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
UCB Pharma
NCT01221948 · Idiopathic Parkinson's Disease
NCT05094011 · Idiopathic Parkinson's Disease
NCT02610231 · Idiopathic Parkinson's Disease
NCT01668407 · Idiopathic Parkinson's Disease, Progressive Supranuclear Palsy
NCT03665493 · Idiopathic Parkinson's Disease
Birmingham, Alabama
St. Petersburg, Florida
Fort Wayne, Indiana
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions